SCHEMBL7934259

SCHEMBL7934259

CC(=O)[C@@H](N)Cc1ccc(C(F)(F)F)cc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRB2 P62993 1/20 0.57
PTPN1 P18031 2/20 0.53
DPP4 P27487 3/20 0.50
FAP Q12884 2/20 0.50
DPP8 Q6V1X1 2/20 0.50
DPP9 Q86TI2 2/20 0.50
DPP7 Q9UHL4 1/20 0.50
TPH1 P17752 2/20 0.46
MAOB P27338 1/20 0.45
PPARG P37231 3/20 0.45
PPARA Q07869 3/20 0.45
EPHX2 P34913 1/20 0.45
SLC7A5 Q01650 2/20 0.44
KIF11 P52732 1/20 0.44
TAAR1 Q96RJ0 1/20 0.44
AKT1 P31749 1/20 0.44
AKT2 P31751 1/20 0.44
AKT3 Q9Y243 1/20 0.44
ALPI P09923 1/20 0.43
PKM P14618 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4672925 1.00 GRB2 (0.57) GRB2PTPN1DPP4FAPDPP8
SCHEMBL12188586 1.00 GRB2 (0.57) GRB2PTPN1DPP4FAPDPP8
SCHEMBL19143516 0.88 GRB2 (0.55) GRB2PTPN1DPP4FAPDPP8
SCHEMBL43862 0.86 GRB2 (0.76) GRB2PTPN1DPP4FAPDPP8
SCHEMBL12323865 0.86 GRB2 (0.57) GRB2PTPN1DPP4FAPDPP8
SCHEMBL148122 0.86 GRB2 (0.76) GRB2PTPN1DPP4FAPDPP8
SCHEMBL43861 0.86 GRB2 (0.76) GRB2PTPN1DPP4FAPDPP8
SCHEMBL2738531 0.86 GRB2 (0.57) GRB2PTPN1DPP4FAPDPP8
SCHEMBL16501752 0.85 GRB2 (0.53) GRB2PTPN1DPP4FAPDPP8
SCHEMBL14288393 0.85 GRB2 (0.53) GRB2PTPN1DPP4FAPDPP8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11814444-B2 Cyclic polypeptides for PCSK9 inhibition RA PHARMACEUTICALS, INC. (US) 2023-11-14 US disclosed
WO-2010016944-A2 ANALOGUES OF GLUCOSE-DEPENDENT INSULINOTROPIC POLYPEPTIDE (GIP) MODIFIED AT N-TERMINAL IPSEN PHARMA S.A.S. (FR) 2010-02-11 WO disclosed
WO-2010016936-A1 PHARMACEUTICAL COMPOSITIONS OF ANALOGUES OF GLUCOSE-DEPENDENT INSULINOTROPIC POLYPEPTIDE IPSEN PHARMA S.A.S. (FR) 2010-02-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11814444-B2 Cyclic polypeptides for PCSK9 inhibition PCSK9, LDLR, PCSK7 GRB2 1230/4885PTPN1 682/4885DPP4 201/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.